Gain Therapeutics

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gains lead drug candidate GT-02287 for the treatment of Parkinsons disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with five trillion compounds in less than 3 months

Rare diseases,neurodegenerative diseases,pharmacological chaperones,lysosomal storage disorders,and oncology

Gain therapeutics operates in the Biotechnology research industry.

Gain therapeutics's revenue is < 1m

Gain therapeutics has 11 - 50 employees.